Ewing Trenton S, Pieper Jason B, Stern Adam W
Department of Veterinary Clinical Medicine, University of Illinois Veterinary Teaching Hospital, 1008 West Hazelwood Drive, Urbana, IL, 61802, USA.
Department of Comparative, Diagnostic, and Population Medicine, College of Veterinary Medicine, University of Florida, PO Box 100123, Gainesville, FL, 32610, USA.
Vet Dermatol. 2019 Feb;30(1):51-e14. doi: 10.1111/vde.12703. Epub 2018 Nov 25.
Limited information is known about the baseline frequency of canine CD20 positive ( ) cutaneous epitheliotropic T-cell lymphoma. A single canine case report has been published.
To characterize the baseline frequency of CD20 staining in cases of canine cutaneous epitheliotropic T-cell lymphoma; to assess its values as a prognostic indicator.
Skin biopsies from 24 client-owned animals diagnosed with cutaneous epitheliotropic lymphoma were assessed.
A retrospective review of medical records from 2011 to 2018. Clinical histories and previous histological and immunohistochemical slides were collected from 24 dogs and additional immunohistochemical staining was performed as needed to assess cases of cutaneous epitheliotropic T-cell lymphoma for CD3, CD20, CD79a and PAX5 staining characteristics. Staining characteristics were assessed for their statistical relationship to median survival time.
Overall median survival time was 189 days following the onset of clinical signs and 99 days following definitive diagnosis; 54% of cases had CD20 staining. There was no statistically significant correlation between staining characteristics and median survival time from onset of signs (P = 0.54) or from diagnosis (P = 0.61).
Canine cutaneous epitheliotropic lymphoma has a higher instance of CD20 positivity than documented previously. This indicates that CD20 staining may be unsuitable to differentiate T-cell and B-cell cutaneous epitheliotropic lymphoma. This also may have therapeutic implications with the advent of canine CD20 monoclonal antibody therapies.
关于犬CD20阳性皮肤亲上皮性T细胞淋巴瘤的基线频率，已知信息有限。仅有一篇犬类病例报告发表。
描述犬皮肤亲上皮性T细胞淋巴瘤病例中CD20染色的基线频率；评估其作为预后指标的价值。
对24只确诊为皮肤亲上皮性淋巴瘤的客户拥有动物的皮肤活检样本进行评估。
回顾性分析2011年至2018年的病历。收集24只犬的临床病史以及之前的组织学和免疫组化切片，并根据需要进行额外的免疫组化染色，以评估皮肤亲上皮性T细胞淋巴瘤病例的CD3、CD20、CD79a和PAX5染色特征。评估染色特征与中位生存时间的统计关系。
临床症状出现后总体中位生存时间为189天，确诊后为99天；54%的病例有CD20染色。染色特征与症状出现后的中位生存时间（P = 0.54）或确诊后的中位生存时间（P = 0.61）之间无统计学显著相关性。
犬皮肤亲上皮性淋巴瘤的CD20阳性率高于先前记录。这表明CD20染色可能不适用于区分T细胞和B细胞皮肤亲上皮性淋巴瘤。随着犬CD20单克隆抗体疗法的出现，这也可能具有治疗意义。
